The market for Penicillins and Streptomycins in dosage form in Switzerland experienced fluctuations over the past decade. Starting at a value of 63.365 million USD in 2013, it peaked in 2016 before declining significantly in 2017. By 2023, the market stood at 49.944 million USD, having decreased continuously since 2021. Recent percentages indicate a year-on-year decline of 1.64% in 2023. Over the past five years, the compound annual growth rate (CAGR) was negative, reflecting an average decline of 1.63% per year.
Future trends to watch for:
- The impact of emerging antibiotic resistance might drive demand for innovative treatments, potentially influencing market dynamics for traditional antibiotics like Penicillins and Streptomycins.
- Regulatory changes and healthcare policies in Switzerland could affect the accessibility and pricing of these medications.
- Technological advancements in drug formulations and delivery mechanisms may create new growth opportunities in this sector.
| # | 33 Countries | US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United States | 4,303,400,000 | 2023 | +0.61% | +1.48% | View data |
| 2 | 2 United Kingdom | 730,000,000 | 2023 | -1.31% | -1.45% | View data |
| 3 | 3 France | 717,200,000 | 2023 | -1.91% | +0.034% | View data |
| 4 | 4 Italy | 622,330,000 | 2023 | -3.96% | -4.86% | View data |
| 5 | 5 Germany | 476,270,000 | 2023 | +1.03% | +1.1% | View data |
| 19 | 19 New Zealand | 59,707,000 | 2023 | -1.18% | -1.53% | View data |
| 20 | 20 Portugal | 50,167,000 | 2023 | +0.83% | -0.0056% | View data |
| 21 | 21 Switzerland | 49,944,000 | 2023 | -1.64% | -1.63% | |
| 22 | 22 Guatemala | 39,329,000 | 2023 | +2.5% | +2.87% | View data |
| 23 | 23 Bolivia | 29,241,000 | 2023 | +3.73% | +6.7% | View data |
